Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals
BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored u...
| Autores: | , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2014 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:2445/109602 |
| Acceso en línea: | https://hdl.handle.net/2445/109602 |
| Access Level: | acceso abierto |
| Palabra clave: | Cèl·lules T VIH (Virus) Antiretrovirals Resposta immunitària Genètica molecular T cells HIV (Viruses) Antiretroviral agents Immune response Molecular genetics |
| id |
ES_f133ad36611dfa9a9684bb2bd9a349bf |
|---|---|
| oai_identifier_str |
oai:recercat.cat:2445/109602 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individualsKawana-Tachikawa, AiLlibre, Josep MaríaBravo, IsabelEscrig, RoserMothe, BeatrizPuig, JordiPuertas Castro, Ma. CarmenMartínez Picado, Francisco JavierBlanco, JuliàManzardo, ChristianMiró Meda, José M. (José María), 1956-Iwamoto, AikichiPozniak, Anton L.Gatell, José M.Clotet, Bonaventura, 1953-Brander, ChristianCèl·lules TVIH (Virus)AntiretroviralsResposta immunitàriaGenètica molecularT cellsHIV (Viruses)Antiretroviral agentsImmune responseMolecular geneticsBACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). RESULTS: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. CONCLUSIONS: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.Public Library of Science (PLoS)2017201720142017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion11 p.application/pdfhttps://hdl.handle.net/2445/109602Articles publicats en revistes (Medicina)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0087334PLoS One, 2014, vol. 9, num. 1, p. e87334https://doi.org/10.1371/journal.pone.0087334cc-by (c) Kawana-Tachikawa, Ai et al., 2014http://creativecommons.org/licenses/by/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1096022026-05-29T05:05:01Z |
| dc.title.none.fl_str_mv |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| title |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| spellingShingle |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals Kawana-Tachikawa, Ai Cèl·lules T VIH (Virus) Antiretrovirals Resposta immunitària Genètica molecular T cells HIV (Viruses) Antiretroviral agents Immune response Molecular genetics |
| title_short |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| title_full |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| title_fullStr |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| title_full_unstemmed |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| title_sort |
Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals |
| dc.creator.none.fl_str_mv |
Kawana-Tachikawa, Ai Llibre, Josep María Bravo, Isabel Escrig, Roser Mothe, Beatriz Puig, Jordi Puertas Castro, Ma. Carmen Martínez Picado, Francisco Javier Blanco, Julià Manzardo, Christian Miró Meda, José M. (José María), 1956- Iwamoto, Aikichi Pozniak, Anton L. Gatell, José M. Clotet, Bonaventura, 1953- Brander, Christian |
| author |
Kawana-Tachikawa, Ai |
| author_facet |
Kawana-Tachikawa, Ai Llibre, Josep María Bravo, Isabel Escrig, Roser Mothe, Beatriz Puig, Jordi Puertas Castro, Ma. Carmen Martínez Picado, Francisco Javier Blanco, Julià Manzardo, Christian Miró Meda, José M. (José María), 1956- Iwamoto, Aikichi Pozniak, Anton L. Gatell, José M. Clotet, Bonaventura, 1953- Brander, Christian |
| author_role |
author |
| author2 |
Llibre, Josep María Bravo, Isabel Escrig, Roser Mothe, Beatriz Puig, Jordi Puertas Castro, Ma. Carmen Martínez Picado, Francisco Javier Blanco, Julià Manzardo, Christian Miró Meda, José M. (José María), 1956- Iwamoto, Aikichi Pozniak, Anton L. Gatell, José M. Clotet, Bonaventura, 1953- Brander, Christian |
| author2_role |
author author author author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Cèl·lules T VIH (Virus) Antiretrovirals Resposta immunitària Genètica molecular T cells HIV (Viruses) Antiretroviral agents Immune response Molecular genetics |
| topic |
Cèl·lules T VIH (Virus) Antiretrovirals Resposta immunitària Genètica molecular T cells HIV (Viruses) Antiretroviral agents Immune response Molecular genetics |
| description |
BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). RESULTS: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. CONCLUSIONS: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies. |
| publishDate |
2014 |
| dc.date.none.fl_str_mv |
2014 2017 2017 2017 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/2445/109602 |
| url |
https://hdl.handle.net/2445/109602 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0087334 PLoS One, 2014, vol. 9, num. 1, p. e87334 https://doi.org/10.1371/journal.pone.0087334 |
| dc.rights.none.fl_str_mv |
cc-by (c) Kawana-Tachikawa, Ai et al., 2014 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
cc-by (c) Kawana-Tachikawa, Ai et al., 2014 http://creativecommons.org/licenses/by/3.0/es |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
11 p. application/pdf |
| dc.publisher.none.fl_str_mv |
Public Library of Science (PLoS) |
| publisher.none.fl_str_mv |
Public Library of Science (PLoS) |
| dc.source.none.fl_str_mv |
Articles publicats en revistes (Medicina) reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869424106917593088 |
| score |
15,812429 |